

GLAXOSMITHKLINE PLC
Form 6-K
October 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
- b) Position/status CEO Designate
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.9675	447.196
- d) Aggregated information
Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.9675	178.878
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2016-10-13	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S A Hussain
b) Position/status	President, Global Pharmaceuticals
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.9675	223.598

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- d) Aggregated information n/a (single transaction)
 Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr B McNamara
 CEO, GSK Consumer
 Healthcare
- b) Position/status
- c) Initial notification/
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted
- a) Description of the financial instrument GlaxoSmithKline plc
 American Depositary Shares
 ('ADSs')
 ISIN: US37733W1053
 Increase in notional interest
 in ADSs following the
 re-investment of dividends
 paid to shareholders on 13
 October 2016 on ADSs held
 in the Company's Deferred
 Investment Award
 Programme.
- b) Nature of the transaction
- c) Price(s) and
 volume(s) Price(s) Volume(s)
 \$42.0900 284.061
- d) Aggregated information n/a (single transaction)
 Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
- c) Initial notification/
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted
- a) Description of the financial instrument

	Ordinary shares of 25 pence each ('Ordinary Shares')				
	ISIN: GB0009252882				
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.9675</td> <td>178.878</td> </tr> </table>	Price(s)	Volume(s)	£16.9675	178.878
Price(s)	Volume(s)				
£16.9675	178.878				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2016-10-13				
f) Place of the transaction	n/a				

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	Senior Vice President, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')				
	ISIN: GB0009252882				
	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.				
b) Nature of the transaction	shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.9675</td> <td>178.878</td> </tr> </table>	Price(s)	Volume(s)	£16.9675	178.878
Price(s)	Volume(s)				
£16.9675	178.878				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2016-10-13				

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance
President, Pharmaceuticals
R&D
- b) Position/status
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.9675 | 223.598 |
- d) Aggregated information
Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: October 17, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc